Beam Therapeutics BEAM 深 沪
等待开盘 01-28 09:30:00 美东时间
30.70
-0.250
-0.81%
华盛通- 最 高32.26
- 今 开30.91
- 成交量 116.72万股
- 最 低 30.32
- 昨 收 30.95
- 总市值 31.01亿
- 52周最高 36.44
- 市盈率 静 --
- 换手率 1.16%
- 52周最低 13.525
- 委 比 25.44%
- 总股本 1.01亿
- 历史最高 138.522
- 量 比 0.51
- 振 幅 6.27%
- 历史最低 13.00
- 每 手 1
- 风险率 4.82%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Today’s Market Recap: Nasdaq Leads Gains Amid Economic Strength
On January 22, 2026, U.S. equities closed higher across the board, with the Nasdaq Composite (+0.91%) leading the day’s rally and finishing at 23,436.02.
01-23 01:04
美股大行评级 | 奈飞绩后遭13家大行下调目标价；齐昂银行、美国合众银行获多家机构上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从9美元升至50美元；韦德布什：维持Ardelyx, Inc."跑赢大市"评级，目标价从16美元升至19美元
01-22 15:09
Beam Therapeutics SVP Finance Bethany J. Cavanagh Reports Disposal of Common Shares
Beam Therapeutics SVP Finance Bethany J. Cavanagh Reports Disposal of Common Shares Bethany J. Cavanagh, SVP, Finance and Treasurer of Beam Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below. Disclaimer: This news brief was
01-22 05:05
Bernstein Maintains Outperform on Beam Therapeutics, Raises Price Target to $41
Bernstein analyst William Pickering maintains Beam Therapeutics (NASDAQ:BEAM) with a Outperform and raises the price target from $37 to $41.
01-21 23:28
U.S. RESEARCH ROUNDUP-IBM, KLA, WEX
U.S. RESEARCH ROUNDUP-IBM, KLA, WEX Jan 21 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including IBM, KLA and WEX, on Wednesday. HIGHLIGHTS * IBM IBM.N : JP Morgan raises target price to $312 from $290 * KLA Corp KLAC.O : Deut
01-21 16:26
美股牛股 | 私人航空公司UP单日暴涨46%！One Stop大涨29%，获美军预生产订单
私人航空公司UP单日暴涨46%！One Stop股价涨29%，获美军预生产订单；BIOA涨逾27%，核心在研药获突破进展>>
01-13 17:24
基因药物开发取得进展 Beam Therapeutics (BEAM.US)股价大涨
Beam Therapeutics发布了关于持续致力于建立可持续、可预测模式以推进精准基因药物开发的最新进展。
01-13 10:16
Beam Therapeutics Stock Surges: What's Driving The Sudden Jump?
Beam Therapeutics shares are popping on Monday after the company laid out a series of pipeline updates and strategic priorities for 2026.
01-13 02:39
Beam Therapeutics outlines 2026 strategy and extends runway
Beam Therapeutics ( ($BEAM) ) just unveiled an announcement. On January 11, 202...
01-12 20:40
Apellis Pharmaceuticals FY25 Preliminary U.S. Net Product Revenues Of $689M
Full-year 2025 preliminary1 U.S. net product revenues of $689 millionSYFOVRE® (pegcetacoplan injection) total injection demand grew 17% year-over-year; regulatory submission for prefilled syringe planned in 1H
01-12 20:10
